BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35561869)

  • 21. [Cancer Vaccine Focused on Neoantigens].
    Shindo Y; Hazama S; Nagano H
    Gan To Kagaku Ryoho; 2019 Sep; 46(9):1367-1371. PubMed ID: 31530772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Research progress of neoantigens in gynecologic cancers.
    Song Y; Zhang Y
    Int Immunopharmacol; 2022 Nov; 112():109236. PubMed ID: 36113318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy.
    Okada M; Shimizu K; Fujii SI
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymph node-targeting nanovaccines for cancer immunotherapy.
    Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
    J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy.
    Zhu G; Mei L; Vishwasrao HD; Jacobson O; Wang Z; Liu Y; Yung BC; Fu X; Jin A; Niu G; Wang Q; Zhang F; Shroff H; Chen X
    Nat Commun; 2017 Nov; 8(1):1482. PubMed ID: 29133898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy.
    Richard G; Princiotta MF; Bridon D; Martin WD; Steinberg GD; De Groot AS
    Expert Rev Vaccines; 2022 Feb; 21(2):173-184. PubMed ID: 34882038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
    Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
    Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoantigen vaccine: an emerging tumor immunotherapy.
    Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
    Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunomodulatory glycomedicine: Introducing next generation cancer glycovaccines.
    Freitas R; Peixoto A; Ferreira E; Miranda A; Santos LL; Ferreira JA
    Biotechnol Adv; 2023; 65():108144. PubMed ID: 37028466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altering Landscape of Cancer Vaccines: Unique Platforms, Research on Therapeutic Applications and Recent Patents.
    Ray SK; Mukherjee S
    Recent Pat Anticancer Drug Discov; 2022; 18(2):133-146. PubMed ID: 35431002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside.
    Roy S; Sethi TK; Taylor D; Kim YJ; Johnson DB
    J Leukoc Biol; 2020 Oct; 108(4):1455-1489. PubMed ID: 32557857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Self-adjuvanting cancer nanovaccines.
    Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
    J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanobiomaterial-based vaccination immunotherapy of cancer.
    Chen F; Wang Y; Gao J; Saeed M; Li T; Wang W; Yu H
    Biomaterials; 2021 Mar; 270():120709. PubMed ID: 33581608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
    Zheng Y; Fu Y; Wang PP; Ding ZY
    Dis Markers; 2022; 2022():8270305. PubMed ID: 35211210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines.
    Roesler AS; Anderson KS
    Methods Mol Biol; 2022; 2410():649-670. PubMed ID: 34914074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New emerging targets in cancer immunotherapy: the role of neoantigens.
    De Mattos-Arruda L; Blanco-Heredia J; Aguilar-Gurrieri C; Carrillo J; Blanco J
    ESMO Open; 2020 Apr; 4(Suppl 3):e000684. PubMed ID: 32269031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer immunotherapy-targeted glypican-3 or neoantigens.
    Shimizu Y; Suzuki T; Yoshikawa T; Tsuchiya N; Sawada Y; Endo I; Nakatsura T
    Cancer Sci; 2018 Mar; 109(3):531-541. PubMed ID: 29285841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.